Tandem Diabetes CareMEX:TNDM 66 PB Ratio is 21.38 as of Jul. 12, 2026, which is 70% above its 10-year median of 12.56. GuruFocus rates MEX:TNDM with a GF Score™ of 66/100 and a GF Value™ of MXN1,446.01. The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Tandem Diabetes Care ranks worse than 87.69% on this metric.
The historical rank and industry rank for Tandem Diabetes Care's PB Ratio or its related term are showing as below:
MEX:TNDM'
s PB Ratio Range Over the Past 10 Years
Min: 2.96 Med: 12.56 Max: 97.4
Current: 7.97
During the past 13 years, Tandem Diabetes Care's highest PB Ratio was 97.40. The lowest was 2.96. And the median was 12.56.
MEX:TNDM's PB Ratio is ranked worse than 87.69% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.065
vs MEX:TNDM: 7.97
During the past 12 months, Tandem Diabetes Care's average Book Value Per Share Growth Rate was -17.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -17.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tandem Diabetes Care was 43.80% per year. The lowest was -52.30% per year. And the median was -11.50% per year.
Back to Basics: PB Ratio
Tandem Diabetes Care (MEX:TNDM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tandem Diabetes Care PB Ratio Related Terms
Tandem Diabetes Care PB Ratio Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Tandem Diabetes Care's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tandem Diabetes Care (MEX:TNDM) has a PB Ratio of 21.38 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tandem Diabetes Care and its competitors. This is 70% above median its historical median of 12.56. Over the past decade, Tandem Diabetes Care's PB Ratio has ranged from 2.96 to 97.40. According to the industry distribution chart, Tandem Diabetes Care ranks #691 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 87.7%.
Is Tandem Diabetes Care's PB Ratio too high?
Tandem Diabetes Care's current PB Ratio of 21.38 is 70% above median its 10-year median of 12.56. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 97.40. The Medical Devices & Instruments industry median PB Ratio is 2.07. Tandem Diabetes Care's value of 21.38 is 935.4% above this industry median. Based on the distribution chart, Tandem Diabetes Care ranks #691 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tandem Diabetes Care has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's PB Ratio compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #691 out of 788 companies for PB Ratio. This places Tandem Diabetes Care in the lower half of its industry. The industry median PB Ratio is 2.07. Tandem Diabetes Care's value of 21.38 is 935.4% above this benchmark. Historically, Tandem Diabetes Care's own PB Ratio has ranged from 2.96 to 97.40 over the past decade. While the company's 10-year median is 12.56 vs. the industry median of 2.07, Tandem Diabetes Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tandem Diabetes Care's current PB Ratio of 21.38 is 935.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current PB Ratio is 21.38, which is 70% above median its own 10-year median of 12.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current PB Ratio of 21.38. The stock's GF Value™ is MXN1,446.01, compared to a current price of MXN745.00 — trading 48.5% below its estimated fair value. The current PB Ratio is 21.38, which is 70% above median its 10-year median of 12.56 and 935.4% above the Medical Devices & Instruments industry median of 2.07. Tandem Diabetes Care's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current PB Ratio is 21.38 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of MXN745.00 is trading 48.5% below its estimated GF Value™ of MXN1,446.01.
Key valuation signals for MEX:TNDM:
PB Ratio: 21.38 (70% above median its 10-year median of 12.56)
GF Value™: MXN1,446.01 vs. price of MXN745.00 (48.5% below fair value)
Industry Position: 935.4% above the Medical Devices & Instruments median (#691 of 788)
No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
66GF Score
Get the complete analysis for MEX:TNDM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TNDM has been successfully added to your 
